Coherus Biosciences Stock Last Dividend Paid
CHRS Stock | USD 1.22 0.04 3.17% |
Coherus BioSciences fundamentals help investors to digest information that contributes to Coherus BioSciences' financial success or failures. It also enables traders to predict the movement of Coherus Stock. The fundamental analysis module provides a way to measure Coherus BioSciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Coherus BioSciences stock.
Coherus | Last Dividend Paid |
Coherus BioSciences Company Last Dividend Paid Analysis
Coherus BioSciences' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Coherus Last Dividend Paid Driver Correlations
Understanding the fundamental principles of building solid financial models for Coherus BioSciences is extremely important. It helps to project a fair market value of Coherus Stock properly, considering its historical fundamentals such as Last Dividend Paid. Since Coherus BioSciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Coherus BioSciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Coherus BioSciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
Competition |
Coherus Additional Paid In Capital
Additional Paid In Capital |
|
Based on the recorded statements, Coherus BioSciences has a Last Dividend Paid of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Coherus BioSciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Coherus BioSciences from analyzing Coherus BioSciences' financial statements. These drivers represent accounts that assess Coherus BioSciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Coherus BioSciences' important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 1.3B | 1.2B | 1.2B | 614.8M | 313.6M | 518.3M | |
Enterprise Value | 1.3B | 1.1B | 1.2B | 1.0B | 691.5M | 539.3M |
Coherus Fundamentals
Return On Equity | -16.57 | ||||
Return On Asset | -0.14 | ||||
Profit Margin | (0) % | ||||
Operating Margin | (0.09) % | ||||
Current Valuation | 317.35 M | ||||
Shares Outstanding | 115.21 M | ||||
Shares Owned By Insiders | 1.39 % | ||||
Shares Owned By Institutions | 70.09 % | ||||
Number Of Shares Shorted | 33.04 M | ||||
Price To Earning | 4.22 X | ||||
Price To Book | 73.19 X | ||||
Price To Sales | 0.48 X | ||||
Revenue | 257.24 M | ||||
Gross Profit | (58.4 M) | ||||
EBITDA | (193.94 M) | ||||
Net Income | (237.89 M) | ||||
Cash And Equivalents | 275.48 M | ||||
Cash Per Share | 3.54 X | ||||
Total Debt | 480.84 M | ||||
Current Ratio | 3.17 X | ||||
Book Value Per Share | (0.76) X | ||||
Cash Flow From Operations | (174.88 M) | ||||
Short Ratio | 12.34 X | ||||
Earnings Per Share | (0.09) X | ||||
Target Price | 6.5 | ||||
Number Of Employees | 235 | ||||
Beta | 0.69 | ||||
Market Capitalization | 145.17 M | ||||
Total Asset | 629.6 M | ||||
Retained Earnings | (1.58 B) | ||||
Working Capital | 143.86 M | ||||
Current Asset | 197.39 M | ||||
Current Liabilities | 106.02 M | ||||
Net Asset | 629.6 M |
About Coherus BioSciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Coherus BioSciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Coherus BioSciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Coherus BioSciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.